Trial Profile
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Ischaemic heart disorders
- Focus Diagnostic use
- 07 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2015 New trial record